Searched for
ZYDUS HOSPIRA
Zydus Lifesciences gets USFDA's nod to market generic version of BortezomibThe drug, a generic version of reference listed drug Velcade, will be manufactured at Zydus Hospira, Gujarat.- Baxter emerges as frontrunner to buy KKR-backed Gland Pharma for $1.1-1.2 billionHyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...
- Gland Pharma promoters put their 60 per cent stake on the blockPromoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block.
- Cadila Healthcare to acquire Claris Lifesciences for Rs 3,400 croreBoth sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said at least five so...
- Claris surges 18% as pharma cos in race to buy injectible bizLupin, Cipla Zydus Cadilla and US-based Amneal are competing with other global peers signaling the continuing appeal of quality Indian phar...
- Big pharma eyes takeover of Claris’ injectables business for Rs 2500-Rs 3000 croreCarlyle private equity backed CLL has transferred its speciality injectables business into a wholly owned subsidiary called CIL.
- Wockhardt, Cadila and Hospira voluntarily recall drugs in USDrug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in US, according to the US Food and Dru...
- Aurobindo Pharma lands in patent litigation cases in USAIndian firm Aurobindo Pharma has been dragged to court by three multi-national drug makers on allegations of patent infringement.
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.
- Zydus Cadila buys out Biochem PharmaceuticalsZydus Cadila has acquired 100% stake in Mumbai-based Biochem Pharmaceuticals for an undisclosed amount.
- Sharekhan recommends ‘buy’ on Cadila HealthcareSharekhan has recommended ‘buy’ on Cadila Healthcare with a target price of Rs.372. At the current market price of Rs272, the stock is avai...
- Zydus bets on off-patent genericsThe company plans to launch 100 drugs in US & Europe over the next five years.
- Hospira-Mayne deal likely to alter pharma equations hereOne of the biggest trans-continent deals in the generic pharma sector is likely open the floodgates of opportunities for the Indian pharma ...
Load More
